First GSDIa gene therapy wins FDA approval
The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit.
The 60-second version
The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit.
Key points
- Genglycos is the first approved GSDIa treatment.
- A 48-week study found a 31% mean reduction in daily cornstarch intake versus placebo.
- Accelerated approval leaves long-term benefit and safety questions to follow-up studies.
Verdict. This is a meaningful new option, not the end of specialist care.
What changedFirst GSDIa gene therapy wins FDA approval
The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit.
Why it mattersGenglycos is the first approved GSDIa treatment.
The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit. Genglycos is the first approved GSDIa treatment. This is a meaningful new option, not the end of specialist care.
Why it mattersA 48-week study found a 31% mean reduction in daily cornstarch intake versus placebo.
The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit. A 48-week study found a 31% mean reduction in daily cornstarch intake versus placebo. This is a meaningful new option, not the end of specialist care.
Why it mattersAccelerated approval leaves long-term benefit and safety questions to follow-up studies.
The FDA approved Genglycos for patients aged eight and older with glycogen storage disease type Ia, while requiring further trials to confirm long-term benefit. Accelerated approval leaves long-term benefit and safety questions to follow-up studies. This is a meaningful new option, not the end of specialist care.
This is a meaningful new option, not the end of specialist care.